Patients with bladder cancer needed for a research study of two immunotherapy drugs (derazantinib and atezolizumab)

UVA Tracking #
HSR200122
Principal Investigator
Robert Dreicer
Contact
Milos Lesevic
Contact Phone
434.243.0544
Official Trial Title
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Study Description

The UVA Cancer Center seeks adults ages 18 and over with urothelial (bladder) cancer for a clinical trial. The purpose of this study is to evaluate a chemotherapy drug (enfortumab vedotin) alone or in combination with other anticancer therapies in patients with urothelial cancer. Disease response and good and bad effects of the drug will be studied as part of this study. Study specific tests will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03288545

Compensation

Up to $200 for hotel stay and up to $100 for travel costs.